Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis
- PMID: 22525304
- DOI: 10.1038/ajg.2012.108
Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis
Erratum in
- Am J Gastroenterol. 2014 Jan;109(1):144
Abstract
Objectives: Several studies have raised concern regarding the possible association between proton-pump inhibitors (PPIs) and Clostridium difficile infection (CDI). We aimed to perform a systematic review of incident and recurrent CDI in PPI users, and to evaluate the relative impact of concurrent antibiotic use, or switching acid suppression to histamine-2-receptor antagonists (H2RAs).
Methods: We searched MEDLINE and EMBASE from inception to December 2011 for controlled observational studies that reported on the risk of CDI with and without PPI use. We performed random effects meta-analysis and assessed statistical heterogeneity using the I(2) statistic.
Results: We included 42 observational studies (30 case-control, 12 cohort) totalling 313,000 participants overall. Pooled analysis of 39 studies showed a statistically significant association between PPI use and risk of developing CDI, odds ratio (OR) 1.74 (95% confidence interval (CI) 1.47-2.85, P<0.001, I(2)=85%) compared with non-users. A pooled analysis of three studies showed a significant associated risk of recurrent CDI associated with PPIs, OR 2.51 (95% CI 1.16-5.44, P=0.005, I(2)=78%). Subgroup analysis failed to fully clarify the source of the substantial statistical heterogeneity. Adjusted indirect comparison demonstrated that use of H2RAs as an alternative carried a lower-risk OR 0.71 (95% CI 0.53-0.97) compared with PPIs. Conversely, concomitant use of PPI and antibiotics conferred a greater-risk OR 1.96 (95% CI 1.03-3.70) above that of PPIs alone. For PPI and antibiotics, the Rothman's synergy index was 1.36 and attributable proportion of risk from interaction 0.19, indicating an increased risk from interaction beyond the effects of each drug alone.
Conclusions: Despite the substantial statistical and clinical heterogeneity, our findings indicate a probable association between PPI use and incident and recurrent CDI. This risk is further increased by concomitant use of antibiotics and PPI, whereas H2RAs may be less harmful.
Comment in
-
How much do PPIs contribute to C. difficile infections?Am J Gastroenterol. 2012 Jul;107(7):1020-1. doi: 10.1038/ajg.2012.174. Am J Gastroenterol. 2012. PMID: 22764024
-
ACP Journal Club: review: proton-pump inhibitors are associated with increased risk for Clostridium difficile infection.Ann Intern Med. 2012 Aug 21;157(4):JC2-13. doi: 10.7326/0003-4819-157-4-201208210-02013. Ann Intern Med. 2012. PMID: 22910967 No abstract available.
-
Proton pump inhibitor use may be associated with an increased risk of Clostridium difficile infection.Evid Based Med. 2013 Oct;18(5):193-4. doi: 10.1136/eb-2012-101057. Epub 2012 Dec 8. Evid Based Med. 2013. PMID: 23220471 No abstract available.
-
Risk of Clostridium difficile infection with acid-suppressive therapy; pitfalls in accurate estimation.Am J Gastroenterol. 2013 Feb;108(2):277-8. doi: 10.1038/ajg.2012.394. Am J Gastroenterol. 2013. PMID: 23381074 No abstract available.
-
Does confounding explain the association between PPIs and Clostridium difficile-related diarrhea?Am J Gastroenterol. 2013 Feb;108(2):278-9. doi: 10.1038/ajg.2012.395. Am J Gastroenterol. 2013. PMID: 23381076 No abstract available.
-
Response to Chandra et al., and Freedberg and Abrams.Am J Gastroenterol. 2013 Feb;108(2):279-80. doi: 10.1038/ajg.2012.397. Am J Gastroenterol. 2013. PMID: 23381077 No abstract available.
Similar articles
-
Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis.JAMA Intern Med. 2017 Jun 1;177(6):784-791. doi: 10.1001/jamainternmed.2017.0212. JAMA Intern Med. 2017. PMID: 28346595 Free PMC article. Review.
-
How much do PPIs contribute to C. difficile infections?Am J Gastroenterol. 2012 Jul;107(7):1020-1. doi: 10.1038/ajg.2012.174. Am J Gastroenterol. 2012. PMID: 22764024
-
Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis.World J Gastroenterol. 2017 Sep 21;23(35):6500-6515. doi: 10.3748/wjg.v23.i35.6500. World J Gastroenterol. 2017. PMID: 29085200 Free PMC article. Review.
-
Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model.J Gastroenterol Hepatol. 2020 Aug;35(8):1325-1330. doi: 10.1111/jgh.14983. Epub 2020 Jan 29. J Gastroenterol Hepatol. 2020. PMID: 31970824
-
Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure.Pharmacoepidemiol Drug Saf. 2011 Oct;20(10):1035-42. doi: 10.1002/pds.2198. Epub 2011 Aug 10. Pharmacoepidemiol Drug Saf. 2011. PMID: 21833992
Cited by
-
Vonoprazan-associated Clostridioides difficile infection: an analysis of the Japanese Adverse Drug Event Report and the FDA Adverse Event Reporting System.Ther Adv Drug Saf. 2024 Jul 31;15:20420986241260211. doi: 10.1177/20420986241260211. eCollection 2024. Ther Adv Drug Saf. 2024. PMID: 39091466 Free PMC article.
-
Insight into the Mechanism of Lysogeny Control of phiCDKH01 Bacteriophage Infecting Clinical Isolate of Clostridioides difficile.Int J Mol Sci. 2024 May 23;25(11):5662. doi: 10.3390/ijms25115662. Int J Mol Sci. 2024. PMID: 38891850 Free PMC article.
-
Approach to the diagnosis and management of dysbiosis.Front Nutr. 2024 Apr 19;11:1330903. doi: 10.3389/fnut.2024.1330903. eCollection 2024. Front Nutr. 2024. PMID: 38706561 Free PMC article. Review.
-
Oral-to-rectum microbial transmission in orthopedic patients without a history of intestinal disorders.Front Cell Infect Microbiol. 2024 Apr 10;14:1358684. doi: 10.3389/fcimb.2024.1358684. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38660493 Free PMC article.
-
Osseous implications of proton pump inhibitor therapy: An umbrella review.Bone Rep. 2024 Feb 1;20:101741. doi: 10.1016/j.bonr.2024.101741. eCollection 2024 Mar. Bone Rep. 2024. PMID: 38348455 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
